Berséus, O., Boman, K., Nessen, S.C., et al. (2013) Risks of Hemolysis Due to Anti-A and Anti-B Caused by the Transfusion of Blood or Blood Components Containing ABO-Incompatible Plasma. Transfusion, 53, 114S-123S.
https://doi.org/10.1111/trf.12045

has been cited by the following article:

• TITLE: System Engineering of Emergent Serum Therapy to Combat COVID-19 and Other Pathogenic Pandemics

  AUTHORS: Peter K. Law

  KEYWORDS: Serum Therapy, Plasma Therapy, COVID-19, Coronavirus, Vaccine, Antibody Medicine, Transfusion Immunology

  JOURNAL NAME: Open Journal of Regenerative Medicine, Vol.9 No.1, March 23, 2020

  ABSTRACT: Life-saving procedures of an emergency protocol to combat fatal ambushes of viral or bacterial pathogens are listed below for immediate dissemination and implementation. This unique protocol of serum therapy commands the highest benefits-versus-risks ratio, and is safe, efficacious, user-friendly and inexpensive to implement. A formal evaluation is presented to support upgrading convalescent plasma therapy to serum therapy in the context of presenting fewer donor antigens, thus evoking less lethal sensitization to obtain greater safety and efficacy in treatment.